← Back to Search
Other
Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome
Darlinghurst, Australia
Phase 1
Waitlist Available
Research Sponsored by Cleave Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new drug for people with certain types of leukemia or myelodysplastic syndrome.
See full description
Eligible Conditions
- Myelodysplastic Syndrome
- Acute Myeloid Leukemia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 28 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Define the MTD and/or RP2D and schedule for CB-5339
Secondary study objectives
Antitumor effects
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: CB-5339Experimental Treatment1 Intervention
Orally administered CB-5339
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CB-5339
2020
Completed Phase 1
~60
Find a Location
Closest Location:Weill Cornel Medical Center· New York, NY
Who is running the clinical trial?
Cleave Therapeutics, Inc.Lead Sponsor
Scott HarrisStudy ChairCleave Therapeutics, Inc.